kabutan

TMS Co., Ltd.(4891) Summary

4891
TSE Growth
TMS Co., Ltd.
135
JPY
-1
(-0.74%)
Dec 5, 2:02 pm JST
0.87
USD
Dec 5, 12:02 am EST
Result
PTS
outside of trading hours
134.7
Dec 5, 2:10 pm JST
Summary Chart Historical News Financial Result
PER
PBR
2.07
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
136 JPY 0.87 USD
Previous Close Dec 4
136 JPY 0.87 USD
High Dec 5, 9:26 am
138 JPY 0.88 USD
Low Dec 5, 1:50 pm
134 JPY 0.86 USD
Volume
145,300
Trading Value
0.02B JPY 0.13M USD
VWAP
135.53 JPY 0.88 USD
Minimum Trading Value
13,500 JPY 87 USD
Market Cap
6.14B JPY 0.04B USD
Number of Trades
43
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Slightly High
1-Year Average
474
1-Year High Feb 7, 2025
8,569
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 3,167,300
Nov 21, 2025 0 3,190,400
Nov 14, 2025 0 3,224,800
Nov 7, 2025 0 3,285,200
Oct 31, 2025 0 3,445,600
Company Profile
TMS Co., Ltd. is a drug discovery bioventure originating from Tokyo University of Agriculture and Technology. The company has partnered with US-based Biogen for its acute ischemic stroke drug candidate.
Sector
Pharmaceuticals
TMS Co., Ltd., a drug discovery bioventure spun off from Tokyo University of Agriculture and Technology, focuses its business on developing TMS-007, a drug candidate for acute ischemic stroke. TMS-007 possesses both thrombolytic and anti-inflammatory properties and has shown promising results in Phase IIa clinical trials. The company has partnered with Hong Kong-based JIXING and retains development and marketing rights for Japan. TMS Co., Ltd. also has multiple pipelines, including TMS-008 for acute kidney injury and cancer cachexia, and JX09, a candidate for hypertension treatment. The company's growth strategy involves in-licensing and developing drug seeds from academia through collaborative research with universities and other institutions, aiming to expand into the global market.